Skip to main content
OpenTrials
Completed

NCT Number: NCT04820712

Surgical Therapy and Survival in HCC/ C.F. Zhang et al.

This study utilizes a new method to explore compare the overall survival (OS) and cancer-specific survival (CSS) in patients aged 18-45 years with stage I-II HCC who underwent different types of surgery. The SEER database, which is one of the most comprehensive and authoritative databases concerning cancer, was used to estimate the survival benefit of patients who underwent local tumor destruction (LTD), wedge or segmental resection (WSR), lobectomy resection (LR), liver transplantation (LT), or non-surgery. This study discovered surgery offered a survival benefit compared with non-surgery for young patients with stage I-II HCC. Furtherly, LT is associated with superior survival than WSR, LR and LTD in those patients. Our results facilitate the selection of surgical strategies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Surgery

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Observational

Primary location

linzhu Zhai

Guangzhou, Guangdong, 510405, China

About this study

The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis. Therefore, the current study was deemed to be exempt from Institutional Review Board approval and the need for informed consent was waived. The submitted magazine requires registration on the website, so this operation is needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients were diagnosed with colorectal cancer only;
  • Patients with simultaneous metastasis of liver and lung cancer cells;
  • Patients without metastasis resection;
  • whether they underwent palliative primary tumor resection was known;
  • Their cause of death was known;
  • Their survival time were known and greater than 0 month;
  • Patients were diagnosed with microscopic confirmation.

Exclusion criteria

  • No

Treatment and study plan

Primary outcomes

  1. Overall survival

    Time frame: 2004.1.1-2013.12.31

    Overall survival was defined as the duration between the surgery and death or the last follow-up

Secondary outcomes

  1. Cancer-specific survival

    Time frame: 2004.1.1-2013.12.31

    Cancer-specific survival was defined as the period between the surgery and death due to cancer to reduce the impact of life-threatening comorbidities.

Sponsors and collaborators

Lead sponsor

Linzhu Zhai

Other

Registry information

Official study title

Surgical Therapy and Survival in Young Patients With Stage I-II Hepatocellular Carcinoma: A Retrospective Cohort Study

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 29, 2021
Registry last updated
Apr 1, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.